Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections.

European journal of clinical pharmacology - 1 Nov 2024

Resztak Matylda, Zalewska Paulina, Wachowiak Jacek, Sobkowiak-Sobierajska Agnieszka, Główka Franciszek K

Abstract excerpt

PURPOSE: Therapeutic drug monitoring (TDM) of voriconazole (VCZ) should be mandatory for all pediatric patients with invasive fungal infections (IFIs). The narrow therapeutic index, inter-individual variability in VCZ pharmacokinetics, and genetic polymorphisms cause achieving therapeutic concentration during therapy to be challenging in this population. METHODS: The study included 44 children suffering from IFIs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal Agents
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Drug Interactions

Share to Drug Monitoring

Share to Immunocompromised Host

Share to Infant

Share to Voriconazole

Source

Open in PubMed Open full text

Identifiers

PMID: 39240338
DOI: 10.1007/s00228-024-03752-z
PMCID: PMC11458732

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections.PMID 39240338Read ↗

Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in childrenSemantic proximity Read ↗

Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients.Semantic proximity Read ↗

Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Semantic proximity Read ↗

Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.Semantic proximity Read ↗

[CYP2C19 genetic polymorphism and monitoring voriconazole plasma concentrations in the treatment and prevention of invasive fungal disease for hematological patients].Semantic proximity Read ↗

<i><scp>CYP</scp>2C19</i> Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?Semantic proximity Read ↗

The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.Semantic proximity Read ↗

Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Semantic proximity Read ↗

Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.Semantic proximity Read ↗

Population pharmacokinetics of voriconazole and CYP2C19 phenotype for dose optimization in hematological patients with invasive fungal infectionsSemantic proximity Read ↗

Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.Semantic proximity Read ↗

Therapeutic drug monitoring of voriconazole.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.